AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02994914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco Geriatric Evaluation
Description: Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy.
Study NCT03447080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: White Bread containing 50g carbohydrate
Study NCT03447080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ricebran soybean milk
Description: White Bread with rice bran soybean milk
Study NCT03447080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean milk
Description: White Bread with soybean milk
Study NCT01431001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Description: The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
Study NCT02150018 — intervention group
Intervention type: OTHER
Intervention: non invasive ventilation
Study NCT03062722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: keyhole approach
Description: The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet orally daily
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet orally daily
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet orally daily
Study NCT01477853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin tablet orally daily
Study NCT01477853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to atorvastatin
Description: Placebo to atorvastatin tablet orally daily.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (open-label)
Description: Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (open-label)
Description: Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (open-label)
Description: Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride (double-blind)
Description: Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
Study NCT01477853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glimepiride
Description: Phase B: placebo to glimepiride tablet orally daily.
Study NCT02098980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT02098980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study NCT00187226 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
Study NCT00187226 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
Study NCT02009670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C inulin
Description: Oral 13C inulin
Study NCT02009670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral maltodextrin
Study NCT01235546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and standard of care
Description: 500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
Study NCT01235546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and standard of care
Description: 250 cc normal saline, plus standard of care (cephazolin or clindamycin)
Study NCT02846090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine to reduce the IOP
Description: Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
Study NCT02846090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine to reduce the IOP
Description: Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
Study NCT01742377 — intervention group
Intervention type: PROCEDURE
Intervention: Patients with GerdQ positive
Description: Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
Study NCT01742377 — intervention group
Intervention type: PROCEDURE
Intervention: Patients with GerdQ negative
Description: Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
Study NCT01742377 — intervention group
Intervention type: PROCEDURE
Intervention: Normal volunteers
Description: Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
Study NCT00003796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study NCT04354987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391 10/10mg
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)
Study NCT04354987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D090, D337
Description: D090 and D337 co-administration(Other Name: Reference drug)
Study NCT02557841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02557841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02557841 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
Study NCT00580814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: methylphenidate treatment
Description: subjects received mehtylphenidate treatment for 12 months
Study NCT01814748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once weekly
Study NCT01814748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
Study NCT01814748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Study NCT01814748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Study NCT01591382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
Study NCT01591382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who received ketamine-matching placebo were given saline infusions
Study NCT01591382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone PCA
Description: Intravenous hydromorphone PCA
Study NCT01591382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone PCA
Description: Intravenous hydromorphone PCA
Study NCT03393195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted Eating plan
Description: Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
Study NCT03393195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consistent Meal timing plan
Description: Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
Study NCT00939874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
Study NCT00330174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 2 333mg tablets three times daily
Study NCT00330174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate
Description: 2 333mg tablets three times daily
Study NCT02231177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL
Study NCT02231177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/Tiotropium FDC
Study NCT02231177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT01954355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: 400, 600 and 800 mg OD
Study NCT01954355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 (days 1, 8, 15)
Study NCT00954148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: 5 visits with PET/CT as only testing
Study NCT00954148 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NCCN recommendations for solid tumor post treatment
Description: 12-14 visits with exams, blood tests, CTs and PET/CT
Study NCT01059630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV infusion.
Study NCT01059630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: IV infusion.
Study NCT02111577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/PCa
Description: DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
Study NCT02111577 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
Study NCT04321174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
Study NCT01059630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV infusion.
Study NCT03532802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: 1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week.
Study NCT03532802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week
Study NCT02403180 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DACP MF
Description: Nelfilcon A multifocal contact lenses
Study NCT02720198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
Study NCT02403180 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PROCLEAR 1D MF
Description: Omafilcon A multifocal contact lenses
Study NCT04334226 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
Study NCT03375281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: thermal ablation using radiofrequency for HCC
Study NCT03610295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPI group
Description: The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
Study NCT03610295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract extraction
Description: The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
Study NCT01896869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
Study NCT01896869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: 5x10\^8 cells administered in 6 intradermal injections
Study NCT01896869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
Study NCT03758963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R:GEN Selective Retina Therapy
Description: Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
Study NCT03758963 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: R:GEN Selective Retina Therapy
Description: Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
Study NCT02054806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01919203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
Study NCT02260453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative coronary angiography
Description: If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
Study NCT02260453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiac workup
Description: EKG, transthoracic cardiac echocardiogram
Study NCT01876290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Ondansetron
Description: Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
Study NCT01876290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03687333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALGLUCOSIDASE ALFA (MYOZYME)
Description: Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion
Study NCT04299893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
Study NCT04299893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study NCT02620176 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: Trans-auricular vagal nerve stimulation
Study NCT02620176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Trans-auricular vagal nerve stimulation
Study NCT01287130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
Study NCT01287130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
Study NCT03888664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma interferon
Description: 1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks